Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages 579-594

  Chabre, O ^a,b,c,d   Libe R ^e,f,g   Assie, G ^e,f,g   Barreau, O ^e,f,g   Bertherat, J ^e,f,g   Bertagna, X ^e,f,g   Feige, J J ^a,c,d   Cherradi, N ^a,c,d  

^a INSERM   (France)

^b HÔPITAL MICHALLON   (France)

^c CEA GRENOBLE   (France)

^d UNIV GRENOBLE ALPES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CNRS   (France)

^g université Paris Cité   (France)

Author keywords

Adrenocortical carcinoma; Biomarker; Circulating miRNA; Diagnosis; Prognosis

Indexed keywords

MICRORNA;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION PROFILING; GENETIC RISK; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADRENOCORTICAL CARCINOMA; BIOMARKER; CIRCULATING MIRNA; DIAGNOSIS; PROGNOSIS;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84882802768     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0051     Document Type: Article

References (36)

1. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 91 2650-2655. (doi:10.1210/jc.2005-2730)
2. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037. (doi:10.1210/jc.2005-2639)
3. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 281-297. (doi:10.1016/S0092-8674(04)00045-5)
4. Bird IM, Hanley NA, Word RA, Mathis JM, McCarthy JL, Mason JI & Rainey WE 1993 Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology 133 1555-1561. (doi:10.1210/en.133.4.1555)
5. Brase JC, Wuttig D, Kuner R & Sultmann H 2010 Serum microRNAs as non-invasive biomarkers for cancer. Molecular Cancer 9 306. (doi:10.1186/1476- 4598-9-306)
6. Calin GA & Croce CM 2006 MicroRNA signatures in human cancers. Nature Reviews. Cancer 6 857-866. (doi:10.1038/nrc1997)
7. Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ & Kerin MJ 2011 MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. International Journal of Colorectal Disease 26 1415-1422. (doi:10.1007/s00384-011-1279-4)
8. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP & Lalli E 2010 Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Research 70 4666-4675. (doi:10.1158/0008-5472.CAN-09-3970)
9. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S & Lichter P 2000 Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes, Chromosomes & Cancer 28 145-152. (doi:10.1002/(SICI)1098-2264(200006)28:2〈145::AID-GCC3〉3. 0.CO;2-7)
10. Esquela-Kerscher A & Slack FJ 2006 Oncomirs - microRNAs with a role in cancer. Nature Reviews. Cancer 6 259-269. (doi:10.1038/nrc1840)
11. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S & Allolio B 2009 Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115 243-250. (doi:10.1002/cncr.24030)
12. Fassnacht M, Libe R, Kroiss M & Allolio B 2011 Adrenocortical carcinoma: a clinician's update. Nature Reviews. Endocrinology 7 323-335. (doi:10.1038/nrendo.2010.235)
13. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B et al. 2012 Combination chemotherapy in advanced adrenocortical carcinoma. New England Journal of Medicine 366 2189-2197. (doi:10.1056/NEJMoa1200966)
14. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E et al. 2005 Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 90 1819-1829. (doi:10.1210/jc.2004-1075)
15. Giordano TJ 2006 Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocrine Pathology 17 355-363. (doi:10.1007/s12022-006-0007-z)
16. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G & Hammer G 2009 Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clinical Cancer Research 15 668-676. (doi:10.1158/1078-0432.CCR-08-1067)
17. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C et al. 2010 Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. Journal of Clinical Oncology 28 1721-1726. (doi:10.1200/JCO.2009.24.9342)
18. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS et al. 2008 Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal of Haematology 141 672-675. (doi:10.1111/j.1365-2141.2008.07077.x)
19. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M et al. 2010 MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. Journal of Clinical Investigation 120 1298-1309. (doi:10.1172/JCI39566)
20. McDonald JS, Milosevic D, Reddi HV, Grebe SK & Algeciras-Schimnich A 2011 Analysis of circulating microRNA: preanalytical and analytical challenges. Clinical Chemistry 57 833-840. (doi:10.1373/clinchem.2010.157198)
21. Melotte V, Lentjes MHFM, van den Bosch SM, Hellebrekers DMEI, de Hoon JPJ, Wouters KAD, Daenen KLJ, Partouns-Hendriks IEJM, Stessels F, Louwagie J et al. 2009 N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. Journal of the National Cancer Institute 101 916-927. (doi:10.1093/jnci/djp131)
22. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al. 2008 Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105 10513-10518. (doi:10.1073/pnas.0804549105)
23. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C & Lui WO 2011 The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrine-Related Cancer 18 643-655. (doi:10.1530/ERC-11-0082)
24. Patterson EE, Holloway AK, Weng J, Fojo T & Kebebew E 2011 MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117 1630-1639. (doi:10.1002/cncr.25724)
25. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML & Duelli DM 2010 Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE 5 e13515. (doi:10.1371/journal.pone.0013515)
26. Qu KZ, Zhang K, Li H, Afdhal NH & Albitar M 2011 Circulating microRNAs as biomarkers for hepatocellular carcinoma. Journal of Clinical Gastroenterology 45 355-360. (doi:10.1097/MCG.0b013e3181f18ac2)
27. Reid G, Kirschner MB & van Zandwijk N 2011 Circulating microRNAs: association with disease and potential use as biomarkers. Critical Review in Oncology and Hematology 80 193-208. (doi:10.1016/j.critrevonc.2010.11.004)
28. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, Dousset B, Bertagna X, Clauser E & Bertherat J 2009 Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology 27 1108-1115. (doi:10.1200/JCO.2008.18.5678)
29. Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, Willscher E, Walz MK, Worm K & Schmid KW 2011 Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. Journal of Clinical Pathology 64 529-535. (doi:10.1136/jcp.2010.085621)
30. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL & Sidhu SB 2009a Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocrine-Related Cancer 16 573-583. (doi:10.1677/ERC-08-0237)
31. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG et al. 2009b miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clinical Cancer Research 15 7684-7692. (doi:10.1158/1078-0432.CCR-09-1587)
32. Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, Ashida S, Miki T, Fujioka T, Shuin T et al. 2009 Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Research 69 8133-8140. (doi:10.1158/0008-5472.CAN-09-0775)
33. Teferedegne B, Murata H, Quinones M, Peden K & Lewis AM 2010 Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro. PLoS ONE 5 e14416. (doi:10.1371/journal.pone.0014416)
34. Tombol Z, Szabo PM, Molnar V, Wiener Z, Tolgyesi G, Horanyi J, Riesz P, Reismann P, Patocs A, Liko I et al. 2009 Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocrine-Related Cancer 16 895-906. (doi:10.1677/ERC-09-0096)
35. Wang F, Zheng Z, Guo J & Ding X 2010 Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecologic Oncology 119 586-593. (doi:10.1016/j.ygyno.2010.07.021)
36. Weiss LM 1984 Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. American Journal of Surgical Pathology 8 163-169. (doi:10.1097/00000478-198403000-00001)